Meeting
2022 ASCO Quality Care Symposium
Real-world racial disparities in EGFR testing and third-generation EGFR TKI use among U.S. patients with stage IV NSCLC.
Authors
Elizabeth Sacchi
EQRx, Cambridge, MA
Elizabeth Sacchi, You Li, Vincent A. Miller, Melissa D. Curtis, Siraj Mahamed Ali
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience
Sub Track
Access to Treatment
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 124)
DOI
10.1200/JCO.2022.40.28_suppl.124
Abstract #
124
Poster Bd #
D23
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Capmatinib plus osimertinib versus platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIb/IIIc or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification.
First Author: Yi-Long Wu
Poster
2023 ASCO Quality Care Symposium
Comparison of molecular testing rates and biomarker positivity by histology among patients (pts) with stage IV non-small cell lung cancer (NSCLC): A quality initiative by Integra Connect PrecisionQ.
First Author: Simon Blanc
Poster
2023 ASCO Quality Care Symposium
Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.
First Author: Kiyoaki Uryu
Poster
2023 ASCO Annual Meeting
EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).
First Author: Amin Nassar